大葉大學圖書館 |

PARP inhibitors for cancer therapy[electronic resource] /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	615.19
書名/作者:	PARP inhibitors for cancer therapy/ edited by Nicola J. Curtin, Ricky A. Sharma.
其他作者:	Curtin, Nicola J.
出版者:	Cham : : Springer International Publishing :, 2015.
面頁冊數:	xix, 591 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	NAD-ADP-ribosyltransferase - Inhibitors
標題:	Enzyme inhibitors - Therapeutic use.
標題:	Cancer - Treatment.
標題:	Biomedicine.
標題:	Cancer Research.
標題:	Drug Resistance.
標題:	Molecular Medicine.
ISBN:	9783319141510 (electronic bk.)
ISBN:	9783319141503 (paper)
內容註:	History of the discovery of poly (ADP-ribose) -- Discovery of the PARP superfamily and focus on the lesser exhibited but not lesser talented members -- The role of PARPs in DNA Strand Break Repair -- TIPs: Tankyrase Interacting Proteins -- PARP and Carcinogenesis -- Multitasking roles for poly(ADP-ribosyl)ation in aging and longevity -- Overview of PARP Inhibitor Design and Optimization -- Structure Based Design of PARP Inhibitors -- Preclinical chemosensitization by PARP inhibitors -- Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents -- Radiosensitisation by poly(ADP-ribose) polymerase inhibition -- The vasoactivity of PARP inhibitors -- Synthetic lethality with Homologous Recombination Repair defects -- Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality -- Other determinants of sensitivity -- Synthetic sickness with molecularly targeted agents against the EGFR pathway -- Disruption of DNA repair by cell cycle and transcriptional CDK inhibition -- Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations -- PARP inhibitor resistance - what is beyond BRCA1 or BRCA2 restoration -- Introduction to PARPi clinical trials and future directions -- Clinical trials investigating PARP inhibitors as single agents -- Clinical trials of PARP inhibitors with chemotherapy -- Combination of PARP inhibitors with clinical radiotherapy -- Biomarkers for PARP Inhibitors.
摘要、提要註:	PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP -poly ADP ribose polymerase- in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discussion of other DNA maintenance-associated PARPs. As well, the volume features a section on the accessible chemistry behind the development of inhibitors. PARP inhibitors -PARPi- are a group of pharmacological inhibitors that are particularly good targets for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA-damaging agents used to treat cancer. Researchers have learned a great deal about the biology of PARP and how tumor-specific defects in DNA repair can be exploited by PARPi. The "synthetic lethality" of PARPi is an exciting concept for cancer therapy, and has led to heightened activity in this area.
電子資源:	http://dx.doi.org/10.1007/978-3-319-14151-0

PARP inhibitors for cancer therapy[electronic resource] /
PARP inhibitors for cancer therapy[electronic resource] /edited by Nicola J. Curtin, Ricky A. Sharma. - Cham :Springer International Publishing :2015. - xix, 591 p. :ill., digital ;24 cm. - Cancer drug discovery and development,v.832196-9906 ;. - Cancer drug discovery and development ;v.82..

History of the discovery of poly (ADP-ribose) -- Discovery of the PARP superfamily and focus on the lesser exhibited but not lesser talented members -- The role of PARPs in DNA Strand Break Repair -- TIPs: Tankyrase Interacting Proteins -- PARP and Carcinogenesis -- Multitasking roles for poly(ADP-ribosyl)ation in aging and longevity -- Overview of PARP Inhibitor Design and Optimization -- Structure Based Design of PARP Inhibitors -- Preclinical chemosensitization by PARP inhibitors -- Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents -- Radiosensitisation by poly(ADP-ribose) polymerase inhibition -- The vasoactivity of PARP inhibitors -- Synthetic lethality with Homologous Recombination Repair defects -- Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality -- Other determinants of sensitivity -- Synthetic sickness with molecularly targeted agents against the EGFR pathway -- Disruption of DNA repair by cell cycle and transcriptional CDK inhibition -- Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations -- PARP inhibitor resistance - what is beyond BRCA1 or BRCA2 restoration -- Introduction to PARPi clinical trials and future directions -- Clinical trials investigating PARP inhibitors as single agents -- Clinical trials of PARP inhibitors with chemotherapy -- Combination of PARP inhibitors with clinical radiotherapy -- Biomarkers for PARP Inhibitors.

PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP -poly ADP ribose polymerase- in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discussion of other DNA maintenance-associated PARPs. As well, the volume features a section on the accessible chemistry behind the development of inhibitors. PARP inhibitors -PARPi- are a group of pharmacological inhibitors that are particularly good targets for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA-damaging agents used to treat cancer. Researchers have learned a great deal about the biology of PARP and how tumor-specific defects in DNA repair can be exploited by PARPi. The "synthetic lethality" of PARPi is an exciting concept for cancer therapy, and has led to heightened activity in this area.

ISBN: 9783319141510 (electronic bk.)

Standard No.: 10.1007/978-3-319-14151-0doiSubjects--Topical Terms:

627665
NAD-ADP-ribosyltransferase
--Inhibitors

LC Class. No.: RM666.E548

Dewey Class. No.: 615.19

PARP inhibitors for cancer therapy[electronic resource] /
LDR:03504nam a2200325 a 4500 001 439576
003 DE-He213
005 20160125094943.0
006 m d
007 cr nn 008maaau
008 160322s2015 gw s 0 eng d
020 $a 9783319141510 (electronic bk.)
020 $a 9783319141503 (paper)
024 7 $a 10.1007/978-3-319-14151-0 $2 doi
035 $a 978-3-319-14151-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RM666.E548
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 615.19 $2 23
090 $a RM666.E548 $b P257 2015
245 0 0 $a PARP inhibitors for cancer therapy $h [electronic resource] / $c edited by Nicola J. Curtin, Ricky A. Sharma.
260 $a Cham : $b Springer International Publishing : $b Imprint: Humana Press, $c 2015.
300 $a xix, 591 p. : $b ill., digital ; $c 24 cm.
490 1 $a Cancer drug discovery and development, $x 2196-9906 ; $v v.83
505 0 $a History of the discovery of poly (ADP-ribose) -- Discovery of the PARP superfamily and focus on the lesser exhibited but not lesser talented members -- The role of PARPs in DNA Strand Break Repair -- TIPs: Tankyrase Interacting Proteins -- PARP and Carcinogenesis -- Multitasking roles for poly(ADP-ribosyl)ation in aging and longevity -- Overview of PARP Inhibitor Design and Optimization -- Structure Based Design of PARP Inhibitors -- Preclinical chemosensitization by PARP inhibitors -- Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents -- Radiosensitisation by poly(ADP-ribose) polymerase inhibition -- The vasoactivity of PARP inhibitors -- Synthetic lethality with Homologous Recombination Repair defects -- Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality -- Other determinants of sensitivity -- Synthetic sickness with molecularly targeted agents against the EGFR pathway -- Disruption of DNA repair by cell cycle and transcriptional CDK inhibition -- Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations -- PARP inhibitor resistance - what is beyond BRCA1 or BRCA2 restoration -- Introduction to PARPi clinical trials and future directions -- Clinical trials investigating PARP inhibitors as single agents -- Clinical trials of PARP inhibitors with chemotherapy -- Combination of PARP inhibitors with clinical radiotherapy -- Biomarkers for PARP Inhibitors.
520 $a PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP -poly ADP ribose polymerase- in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discussion of other DNA maintenance-associated PARPs. As well, the volume features a section on the accessible chemistry behind the development of inhibitors. PARP inhibitors -PARPi- are a group of pharmacological inhibitors that are particularly good targets for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA-damaging agents used to treat cancer. Researchers have learned a great deal about the biology of PARP and how tumor-specific defects in DNA repair can be exploited by PARPi. The "synthetic lethality" of PARPi is an exciting concept for cancer therapy, and has led to heightened activity in this area.
650 0 $a NAD-ADP-ribosyltransferase $x Inhibitors $x Therapeutic use. $3 627665
650 0 $a Enzyme inhibitors $x Therapeutic use. $3 487883
650 0 $a Cancer $x Treatment. $3 338599
650 1 4 $a Biomedicine. $3 463454
650 2 4 $a Cancer Research. $3 463530
650 2 4 $a Drug Resistance. $3 466595
650 2 4 $a Molecular Medicine. $3 463625
700 1 $a Curtin, Nicola J. $3 627663
700 1 $a Sharma, Ricky A. $3 627664
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
830 0 $a Cancer drug discovery and development ; $v v.82. $3 603797
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-14151-0
950 $a Medicine (Springer-11650)